Genprex

Category: Media Coverage

Note: When you click on media articles below, a new page will open indicating that you are leaving the Genprex, Inc. website and entering a third-party website not affiliated with Genprex Inc. or any of its affiliates. No information contained in a linked site has been endorsed or approved by Genprex, Inc. and Genprex, Inc. is not responsible for the content of such third-party websites.

Genprex cancer gene therapy paired with AZ, Merck lung cancer drugs

An experimental gene therapy developed by Texas biotech Genprex will be paired with AstraZeneca’s Tagrisso and Merck & Co’s Keytruda – both leading their respective drug classes in the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Combine Reqorsa With Checkpoint, EGFR Inhibitors in Lung Cancer Studies

Genprex announced that quaratusugene ozeplasmid (Reqorsa) will be studied in two new trials, in which non-small cell lung cancer patients with specific molecular markers will receive its investigational drug combined with osimertinib (AstraZeneca’s Tagrisso) or pembrolizumab (Merck’s Keytruda).

Read More

Genetic Engineering, No Virus Required

Companies are optimizing nonviral delivery methods for commercial use

Read More

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Read More

In pharma, cancer is king

Inside the industry’s quest for its next crowning achievement in oncology.

Read More

Texas company licenses University of Pittsburgh gene therapy that could cure diabetes

A UPMC Children’s Hospital of Pittsburgh researcher is crediting a new, supportive environment for entrepreneurs at the University of Pittsburgh for making it possible to license a technology that may one day cure diabetes.

Read More

Austin’s Genprex raises $25.5M with 2 stock offerings

Austin-based biotech firm Genprex is looking for more growth after raising about $25.5 million through two recent stock offerings.

Read More

Drug Candidate for Lung Cancer Receives FDA Fast Track Designation

Technology Networks spoke with Rodney Varner, CEO of Genprex, to learn more about the next steps for Oncoprex and how the FDA Fast Track Designation will facilitate the delivery of this drug to cancer patients.

Read More

UPMC Children’s Hospital Researchers Working On ‘Groundbreaking’ Procedure To Cure Diabetes

Thirty million Americans are living with diabetes and hoping someday to be cured. That day could come sooner than expected, thanks to a team of researchers at UPMC Children’s Hospital of Pittsburgh.

Read More

Genprex to Focus on Developing Immunogene Therapy, Start Lung Cancer Trials This Year

Genprex said that after receiving the US Food and Drug Administration’s fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.

Read More